NeuroPace Inc
Close on Oct 19, 2026
- Market cap
- $435.51M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About NeuroPace
Surgical & Medical Instruments & Apparatus, SIC 3841
The company develops and commercializes medical devices designed to treat epilepsy by reducing or eliminating seizures. Its primary product is the RNS System, a brain-responsive neuromodulation system that continuously monitors intracranial brain activity, identifies individualized abnormal patterns, and delivers targeted electrical pulses to the seizure origin. In addition to the implantable neurostimulator and lead components, the platform includes clinician and patient management tools such as the Patient Remote Monitor, the Physician Tablet, the Patient Data Management System, and the nSight Platform. Its customer base consists of epileptologists, functional neurosurgeons, and comprehensive epilepsy centers treating adult patients with drug-resistant focal epilepsy.
The company's commercial operations are concentrated primarily in the United States across more than 230 Level 4 comprehensive epilepsy centers as well as outpatient community settings. Its commercial reach also includes distribution in Israel and case-by-case availability through a special access program in Canada. Over 8,000 patients have received the RNS System.
Summary of the business section of NeuroPace's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NeuroPace Inc
- Headquarters
- Mountain View, CA
- Address
- 455 N. Bernardo Avenue 94043
- Phone
- (650) 237-2700
- Website
- www.neuropace.com
- Employees
- 209, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers, San Jose, California
Stock & identifiers
- Ticker
- NPCE
- Exchange
- Nasdaq
- IPO date
- Apr 23, 2021
- Shares outstanding
- 34M, Aug 7, 2026
- Public float
- $306.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1528287
- CUSIP
- 641288105
- ISIN
- US6412881053
- EIN
- 22-3550230
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joel Becker | CHIEF EXECUTIVE OFFICER, Director | 138,000 |
| Martha Morrell | CHIEF MEDICAL OFFICER | 51,357 |
| Patrick F. Williams | Chief Financial Officer | 67,508 |
| Rebecca Kuhn | CHIEF FINANCIAL OFFICER | 131,613 |
| Uri Geiger | Director | 4,451,485 |
| Rakhi Kumar | Director | 23,039 |
| Frank M. Fischer | Director | 599,534 |
| R. Scott Huennekens | Director | 2,890 |
| Renee Ryan | Director | 2,890 |
| Lisa Andrade | Director | 2,890 |
| Joseph Lacob | Director | 238,308 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 209 employees, all of which are based in the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 23, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 14, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |